PharmacoEconomics & Outcomes News 792, p19 - 2 Dec 2017 Menotropin cost effective for ART in France Menotropin (high purified human menopausal gonadotropin [HP-hMG]) appears to be cost effective compared with rFSH (recombinant follicle stimulating hormone) for assisted reproductive technology (ART) in France, according to findings of a study published in Applied Health Economics and Health Policy. A Markov model populated with data from the MERIT and MEGASET trials, or routine ART practice in France, was used to compare the cost effectiveness of menotropin and rFSH in a hypothetical cohort of 30 000 patients undergoing in vitro fertilization/ intracytoplasmic sperm injection (IVF/ICSI) with embryo transfer, from a French healthcare payer perspective. Based on clinical trial data, the estimated total cost per live birth was lower with menotropin than with rFSH (€12 145 vs €14 247), resulting in an estimated incremental cost-effectiveness ratio (ICER) of –€11 616 per live birth. Menotropin was estimated to gain 1289 additional live births compared with rFSH at cost savings of €15.0 million in the total cohort, and was therefore the dominant strategy (more effective and less costly). Based on French clinical data, the estimated cost per live birth was €16 415 with menotropin and €18 7531 with rFSH, resulting in an ICER of –€7719 per live birth. Menotropin was estimated to gain 1097 additional live births compared with rFSH at cost savings of €8.54 million in the total cohort, and was therefore dominant. According to deterministic sensitivity analyses, live birth rate and total gonadotropin doses were the primary drivers of cost effectiveness. Probabilistic sensitivity analysis found that menotropin was the dominant strategy in 71.2% of cases based on clinical trial data and in 50.2% of cases based on French clinical data. "This study highlighted the high total costs of ART in France and demonstrated that potential savings related to the use of a less expensive gonadotropin are higher as effectiveness increases," said the authors. "The results of the present Markov model analysis are consistent with previous findings in other European countries," they noted. * 2016 euros Barriere P, et al. Cost-Effectiveness Analysis of the Gonadotropin Treatments HP- hMG and rFSH for Assisted Reproductive Technology in France: A Markov Model Analysis. Applied Health Economics and Health Policy : 9 Nov 2017. Available from: URL: http://doi.org/10.1007/s40258-017-0361-7 803283344 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792
PharmacoEconomics & Outcomes News – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera